Key Highlights

  • Mike Southard has resigned as a director of Nova Eye Medical after serving on the Board since July 2018.
  • Mr Southard previously spent 26 years with Alcon Laboratories, where he was Vice President of the Global Surgical business.
  • An Appendix 3Z reflecting his final relevant security holdings will be lodged within five business days under Listing Rule 3.19A.
  • Chair Victor Previn thanked Mr Southard for his contribution to the Board and management team over eight years.

Nova Eye Medical Limited (ASX:EYE) announced on 23 October 2026 that Mr Mike Southard has resigned as a director of the company, ending eight years of service on the Board. The company, a medical technology business focused on advanced ophthalmic treatment technologies and devices, said Mr Southard joined the Board in July 2018.

Background of the Departing Director

Nova Eye Medical said Mr Southard brought international ophthalmic industry experience to the Board during his time as a director. His career in the global ophthalmic industry included 26 years with Alcon Laboratories, where he served as Vice President of the Global Surgical business. The company said this experience gave the Board commercial and strategic insight, particularly in relation to the US market, international commercialisation and the development of Nova Eye's glaucoma surgical business.

The Board thanked him for his commitment, counsel and support. Chair Victor Previn said Mr Southard had been a valued member of the Board and had made an important contribution over the past eight years. He said Mr Southard's deep knowledge of the ophthalmic industry, particularly the US surgical market, and his extensive industry relationships had been of considerable value to the Board and management team.

Why This Could Matter

The announcement records a change to the Board. The company said an Appendix 3Z, the Final Director's Interest Notice, will be lodged with the ASX within five business days in accordance with ASX Listing Rule 3.19A. That notice will reflect Mr Southard's final relevant security holdings.

About Nova Eye Medical

Nova Eye Medical develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices used by eye surgeons globally. These include iTrack Advance, a minimally invasive consumable glaucoma surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company also offers the Molteno3 glaucoma drainage device platform, which is designed to enhance surgical utility and optimise clinical outcomes for long-term intraocular pressure control in cases of severe glaucoma.

Its sales headquarters is in Fremont, California, supported by a global network of distribution partners, and its manufacturing facilities are in Fremont and Dunedin, New Zealand.

In Summary

Mr Southard's departure ends a tenure that began in July 2018, and the final director's interest notice is due within five business days.